| A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors (NCT03203876) | Bristol-Myers Squibb | 2017-07-14 |
| Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma (NCT03219775) | AIO-Studien-gGmbH | 2017-07-06 |
| A Phase I Study of TQ-B3101 on Tolerance and Pharmacokinetics (NCT03019276) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2017-07-05 |
| A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors (NCT03192943) | Bristol-Myers Squibb | 2017-06-23 |
| A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread (NCT03098550) | Bristol-Myers Squibb | 2017-06-15 |
| A Phase I Study of TQ-B3234 on Tolerance and Pharmacokinetics (NCT02996838) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2017-05-11 |
| First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors (NCT03110107) | Bristol-Myers Squibb | 2017-05-04 |
| Primary Palliative Care for Patients With Advanced Hematologic Malignancies (NCT02992171) | University of Pittsburgh | 2017-05-02 |
| A Study of AGEN2034 in Advanced Tumors and Cervical Cancer (NCT03104699) | Agenus Inc. | 2017-04-11 |
| Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial (NCT03104335) | Peking University People's Hospital | 2017-04-01 |
| Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations (NCT02747797) | Teresa Helsten, MD | 2017-04-01 |
| Oncology Associated Symptoms & Individualized Strategies (NCT03122249) | Stephanie Gilbertson-White | 2017-03-10 |
| Randomized Study of a Hospice Video Educational Tool for Patients With Advanced Cancer and Their Caregivers (NCT03040102) | Massachusetts General Hospital | 2017-03-09 |
| A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer (NCT03027284) | Eli Lilly and Company | 2017-02-03 |
| A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01) (NCT03013218) | ALX Oncology Inc. | 2017-02-03 |
| A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (NCT02996110) | Bristol-Myers Squibb | 2017-02-02 |
| Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLC (NCT03008109) | Zaiwen Fan | 2017-02-01 |
| Organ-sparing With TraceIT® for Rectal Cancer Radiotherapy (NCT03258541) | Thomas Zilli | 2017-01-15 |
| Immunotherapy And Palliative Radiotherapy Combined In Patients With Advanced Malignancy (NCT03042156) | University Health Network, Toronto | 2017-01-10 |
| Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced Cancer (NCT02992977) | Agenus Inc. | 2017-01-01 |
| Collaborative Care Intervention for Cancer Caregivers (NCT02944136) | University of Pittsburgh | 2016-12-01 |
| Lenvatinib and Capecitabine in Patients With Advanced Malignancies (NCT02915172) | M.D. Anderson Cancer Center | 2016-12-01 |
| A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers (NCT02797795) | Neovia Oncology Ltd. | 2016-12-01 |
| Biomarkers For Immune Checkpoint Inhibitors (NCT04204434) | Rhode Island Hospital | 2016-11-29 |
| A Study of Anti-Lewis Y Chimeric Antigen Receptor-T Cells (LeY-CAR-T) in Patients With Solid Tumours (NCT03851146) | Peter MacCallum Cancer Centre, Australia | 2016-11-24 |
| A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients (NCT04237805) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 2016-11-14 |
| Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During an Outpatient Palliative Care Visit (NCT02957565) | M.D. Anderson Cancer Center | 2016-11-03 |
| Autologous Cytokine-induced Killer Cells Combined Chemotherapy in Advanced Pancreatic Cancer (NCT03002831) | Henan Cancer Hospital | 2016-11-01 |
| A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents (NCT02745769) | Eli Lilly and Company | 2016-10-21 |
| Phase 1 Study of Mesothelin-ADC (NCT02884726) | Bristol-Myers Squibb | 2016-10-14 |
| A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer (NCT02857270) | Eli Lilly and Company | 2016-09-29 |
| A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer (NCT02778126) | Eli Lilly and Company | 2016-09-22 |
| RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD) (NCT02801097) | EpicentRx, Inc. | 2016-08-30 |
| A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer (NCT02860780) | Eli Lilly and Company | 2016-08-10 |
| A Primary Palliative Care Intervention for Patients With Advanced Cancer (NCT02712229) | University of Pittsburgh | 2016-07-27 |
| An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer (NCT02743494) | Bristol-Myers Squibb | 2016-07-14 |
| Quality of Life Intervention for Patients Receiving Radiation Therapy for Advanced Cancer Treatment and Their Caregivers (NCT03094780) | Mayo Clinic | 2016-07-01 |
| Feasibility of Home vs. Hospital Based Resistance Training for Advanced Cancer Patients (NCT02930876) | King's College London | 2016-07-01 |
| An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread (NCT02737475) | Bristol-Myers Squibb | 2016-06-17 |
| Feasibility of Dignity Therapy Intervention on Cancer Patients in Charge to an Hospital Palliative Care Unit. (NCT04738305) | Azienda USL Reggio Emilia - IRCCS | 2016-06-01 |
| Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC (NCT02805660) | Mirati Therapeutics Inc. | 2016-06-01 |
| Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers (NCT02777710) | Centre Leon Berard | 2016-06-01 |
| A Phase I Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer Patients (NCT02825563) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2016-06-01 |
| A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer (NCT02711553) | Eli Lilly and Company | 2016-05-19 |
| An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer (NCT02750514) | Bristol-Myers Squibb | 2016-05-09 |
| A Study of AL2846 on Tolerance and Pharmacokinetics (NCT02779699) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2016-05-01 |
| An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread (NCT02658890) | Bristol-Myers Squibb | 2016-04-14 |
| Online Information and Support for Distance Caregivers (NCT02666183) | Case Comprehensive Cancer Center | 2016-04-06 |
| Pharmacokinetics of Systemic Anti-Cancer Therapies in the Cerebrospinal Fluid (CSF) of Patients With Advanced Cancer (NCT02580045) | Duke University | 2016-04-01 |
| Safety and Pharmacokinetic Study of TRX-818 in Asian Solid Tumor Patients (NCT02703298) | TaiRx, Inc. | 2016-03-25 |
| DM-CHOC-PEN Plus Radiation for Brain Tumors (NCT03371004) | DEKK-TEC, Inc. | 2016-02-05 |
| Transcutaneous Electrical Nerve Stimulation (TENS) for Advanced Cancer Pain Patients (NCT02655289) | University Hospital Freiburg | 2016-02-01 |
| A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer (NCT02671955) | Janssen Research & Development, LLC | 2016-01-01 |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) (NCT02628067) | Merck Sharp & Dohme LLC | 2015-12-18 |
| A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors (NCT02642016) | Celldex Therapeutics | 2015-12-01 |
| A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) (NCT02554812) | Pfizer | 2015-11-09 |
| A Study to Assess the Pharmacokinetic (PK) Properties of Sativex® in Patients With Advanced Cancer (NCT02432612) | GW Pharmaceuticals Ltd | 2015-10-01 |
| Randomized Controlled Trial of the Meaning-Making Intervention (MMi) In Newly Diagnosed Advanced Cancer (NCT02583932) | Jewish General Hospital | 2015-10-01 |
| A Study of LY3076226 in Participants With Advanced or Metastatic Cancer (NCT02529553) | Eli Lilly and Company | 2015-09-01 |
| A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer (NCT02507544) | TaiRx, Inc. | 2015-09-01 |
| Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors (NCT02684318) | Poveda, Andrés, M.D. | 2015-07-01 |
| Caregiver-Guided Pain Management Training in Palliative Care (NCT02430467) | Duke University | 2015-07-01 |
| A Study of BMS-986148 in Patients With Select Advanced Solid Tumors (NCT02341625) | Bristol-Myers Squibb | 2015-06-19 |
| Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors (NCT02407990) | BeiGene | 2015-06-02 |
| Identifying Family Members in Need of Support While Caregiving and After Loss (NCT02455505) | Memorial Sloan Kettering Cancer Center | 2015-05-01 |
| Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer (NCT02418624) | The Netherlands Cancer Institute | 2015-05-01 |
| Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus) (NCT02423954) | Western Regional Medical Center | 2015-04-01 |
| A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma (NCT02383368) | Astellas Pharma Global Development, Inc. | 2015-03-23 |
| A Study of Sinotecean on Tolerance and Pharmacokinetics (NCT02469883) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2015-03-01 |
| Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies (NCT02383212) | Regeneron Pharmaceuticals | 2015-02-02 |
| Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) (NCT02331251) | Western Regional Medical Center | 2014-12-01 |
| Early, Integrated, Specialized Palliative Rehabilitation (NCT02332317) | Vejle Hospital | 2014-12-01 |
| Symptom Management, Quality of Life and Satisfaction With Care for Advanced Stage Cancers - Control Arm (NCT02261051) | Lancaster General Hospital | 2014-10-01 |
| Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer (NCT02318901) | Western Regional Medical Center | 2014-10-01 |
| Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers (NCT02245204) | Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd | 2014-09-01 |
| Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer (NCT02219711) | Mirati Therapeutics Inc. | 2014-08-01 |
| Real-world Clinical Effectiveness of Whole Genome and Transcriptome Analysis to Guide Advanced Cancer Care (NCT04141397) | British Columbia Cancer Agency | 2014-07-01 |
| A Pilot Study Treatment of Malignant Tumors Using [18F] Fluorodeoxyglucose (FDG) (NCT02130492) | Weill Medical College of Cornell University | 2014-05-01 |
| Phase 1 Trial of Chlorogenic Acid in Patients With Advanced Cancer (NCT02136342) | Chinese Academy of Medical Sciences | 2014-05-01 |
| Meaning-Centered Counseling for Chinese Patients Who Are Being Treated for Advanced Cancer (NCT02112188) | Memorial Sloan Kettering Cancer Center | 2014-04-01 |
| Identifying Molecular Drivers of Cancer (NCT02470715) | Avera McKennan Hospital & University Health Center | 2014-04-01 |
| Trial of Olaparib in Combination With AZD5363 (ComPAKT) (NCT02338622) | Royal Marsden NHS Foundation Trust | 2014-03-31 |
| A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer (NCT02082210) | Eli Lilly and Company | 2014-03-07 |
| A Study of CFI-400945 Fumarate in Patients With Advanced Cancer (NCT01954316) | University Health Network, Toronto | 2014-03-01 |
| Phase 1 Trial of CXD101 in Patients With Advanced Cancer (NCT01977638) | Oxford University Hospitals NHS Trust | 2014-02-14 |
| A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety (NCT01976143) | Nektar Therapeutics | 2014-02-01 |
| A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors (NCT02014909) | Celldex Therapeutics | 2014-01-01 |
| A Structured Early Palliative Care Intervention for Patients With Advanced Cancer - a Randomized Controlled Trial With a Nested Qualitative Study (SENS Trial) (NCT01983956) | Insel Gruppe AG, University Hospital Bern | 2013-12-23 |
| Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma (NCT03168035) | NanoCarrier Co., Ltd. | 2013-11-01 |
| An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies (NCT01929941) | Incyte Corporation | 2013-09-01 |
| Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer (NCT01583777) | Acrotech Biopharma Inc. | 2013-09-01 |
| Yoga for Adolescent and Young Adult Non-Curative Cancer Patients (NCT01901237) | Rob Rutledge | 2013-09-01 |
| Engagement of Patients With Advanced Cancer (NCT02966509) | Stanford University | 2013-08-01 |
| Combination of Metformin With Gefitinib to Treat NSCLC (NCT01864681) | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 2013-05-01 |
| Message: Study of Patients' Perception of Physician's Compassion (NCT02357108) | M.D. Anderson Cancer Center | 2013-05-01 |
| Phase 1 Study of CM082 (X-82) Tablets in Advanced Cancer Patients in China (NCT01863485) | AnewPharma | 2013-05-01 |
| A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel. (NCT02193633) | Royal Marsden NHS Foundation Trust | 2013-04-26 |
| Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer (NCT01596140) | M.D. Anderson Cancer Center | 2012-12-18 |
| A Study of MK-8109 (Vintafolide) Given Alone or With Chemotherapy in Participants With Advanced Cancers (MK-8109-001) (NCT01688791) | Endocyte | 2012-12-01 |
| Randomized Controlled Trial of the Meaning-Making Intervention (MMi) (NCT01693991) | Jewish General Hospital | 2012-10-01 |